Assessing EUS and Percutaneous Untargeted Liver Biopsy Quality: A Sequential-Period Cluster-Randomized Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 146
- 试验地点
- 1
- 主要终点
- Biopsy specimen length and complete portal tracts
研究概览
简要总结
This prospective, single-center study evaluates and compares the tissue sample quality and patient comfort of different liver biopsy methods. While traditional percutaneous liver biopsy passes a needle through the abdominal wall into the liver, endoscopic ultrasound-guided liver biopsy (EUS-LB) offers an internal alternative performed via the stomach under sedation. However, the optimal EUS needle size and tip design remain unclear. Therefore, this trial directly compares the diagnostic tissue yield and patient-reported pain across four contemporary EUS needle strategies and the traditional percutaneous approach. The study utilizes a sequential-period cluster-randomized design, enrolling consecutive adult patients who require a clinically indicated, untargeted liver biopsy over five predefined, sequential eight-week periods. Each eight-week block serves as a cluster, during which all enrolled patients receive the specific biopsy needle assigned to that period. The trial begins with the standard percutaneous 18G TruCut needle cluster. To minimize bias, the sequence of the subsequent four EUS-guided needle clusters-consisting of 19G FNA, 19G FNB, 22G FNA, and 22G FNB needles-is determined beforehand using a computer-generated random sequence. All procedures are performed by the same clinical team using highly standardized techniques to compare total specimen length, complete portal tracts, and procedure-associated pain across all groups.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •clinical indication for non-targeted liver biopsy
- •written informed consent
排除标准
- •severe coagulopathy (INR >2.0 or platelet count <50 × 10³/µl)
- •contraindications to endoscopy or sedation
- •anatomical conditions precluding safe liver biopsy
- •pregnancy
研究组 & 干预措施
Percutaneous Liver Biopsy 18G Trucut
干预措施: PC-LB 18G Trucut (Diagnostic Test)
EUS-LB 19G FNA
干预措施: EUS Liver biopsy 19G FNA (Diagnostic Test)
EUS-LB 19G FNB
干预措施: EUS LB 19G FNB (Diagnostic Test)
EUS-LB 22G FNA
干预措施: EUS LB 22G FNA (Diagnostic Test)
EUS-LB 22G FNB
干预措施: EUS LB 22G FNB (Diagnostic Test)
结局指标
主要结局
Biopsy specimen length and complete portal tracts
时间窗: From enrollment within one week
Biopsy specimen length
时间窗: From enrollment within one week
Number of complete portal tracts
时间窗: From enrollment within one week
次要结局
- Adverse events(72 hours)
- Overall adequacy(7 days (until pathologic examination finished))
- Number of complete portal tracts ≥ 11(7 days (until pathologic examination finished))
研究者
Prof. Dr. Michael Praktiknjo
Professor of hepatology
University Hospital Muenster
